Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Morepen Laboratories's operating cash flow per share for the
three
months ended in Jun. 2026 was ₹0.00.
Morepen Laboratories's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2026 was ₹0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Morepen Laboratories's Operating Cash Flow per Share or its related term are showing as below:
During the past 13 years, Morepen Laboratories's highest 3-Year average Operating Cash Flow per Share Growth Rate was 67.60% per year. The lowest was -76.80% per year. And the median was 7.80% per year.
NSE:MOREPENLAB's 3-Year OCF Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.3 * Ranked among companies with meaningful 3-Year OCF Growth Rate only.
Morepen Laboratories Operating Cash Flow per Share Related Terms
Morepen Laboratories Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Morepen Laboratories's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Morepen Laboratories Operating Cash Flow per Share Chart
NSE:MOREPENLAB vs ZTS: Operating Cash Flow per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Morepen Laboratories Price-to-Operating-Cash-Flow vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Morepen Laboratories's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of ₹0.00 mean?
Morepen Laboratories (NSE:MOREPENLAB) has a Operating Cash Flow per Share of ₹0.00 as of Jun. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Morepen Laboratories and its competitors. According to the industry distribution chart, Morepen Laboratories ranks #999999 out of 760 companies in the Drug Manufacturers industry.
Is Morepen Laboratories' Operating Cash Flow per Share too high?
Morepen Laboratories' current Operating Cash Flow per Share is ₹0.00. Based on the distribution chart, Morepen Laboratories ranks #999999 out of 760 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Morepen Laboratories has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' Operating Cash Flow per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Morepen Laboratories ranks #999999 out of 760 companies for Operating Cash Flow per Share. This places Morepen Laboratories in the lower half of its industry. The industry median Operating Cash Flow per Share is 7.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Drug Manufacturers company?
The median Operating Cash Flow per Share among Drug Manufacturers companies is 7.30, based on 760 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Morepen Laboratories and its competitors. For the Drug Manufacturers industry, the median Operating Cash Flow per Share is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Morepen Laboratories's current Operating Cash Flow per Share is ₹0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹54.54, compared to a current price of ₹115.28 — trading 111.4% above its estimated fair value. The current Operating Cash Flow per Share is ₹0.00. Morepen Laboratories' overall GF Score™ is 64/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current Operating Cash Flow per Share is ₹0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued.
The current stock price of ₹115.28 is trading 111.4% above its estimated GF Value™ of ₹54.54.
GuruFocus considers Morepen Laboratories to be Significantly Overvalued.
Key valuation signals for NSE:MOREPENLAB:
Operating Cash Flow per Share: ₹0.00
GF Value™: ₹54.54 vs. price of ₹115.28 (111.4% above fair value)
No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
64GF Score
Get the complete analysis for NSE:MOREPENLAB
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MOREPENLAB has been successfully added to your 
